Seroflo represents a significant advancement in respiratory medicine, combining two proven therapeutic agents into a single, convenient inhaler device. This fixed-dose combination inhaler contains Fluticasone Propionate, a potent inhaled corticosteroid (ICS), and Salmeterol, a long-acting beta2-agonist (LABA), working synergistically to provide comprehensive management of obstructive airway diseases. Designed for maintenance treatment, Seroflo addresses both inflammation and bronchoconstriction—the dual pathological mechanisms underlying asthma and COPD. Its metered-dose inhaler (MDI) delivery system ensures consistent dosing and deep lung deposition, making it a cornerstone therapy in modern pulmonary practice.

Features

• Contains Fluticasone Propionate (ICS) and Salmeterol (LABA) in precise fixed-dose combination
• Available in multiple strength variations (e.g., 50/25 mcg, 125/25 mcg, 250/25 mcg per puff)
• Hydrofluoroalkane (HFA) propellant with minimal environmental impact
• Dose counter to track remaining medication
• Consistent micronized particle size for optimal lung deposition
• Breath-activated mechanism in some formulations
• Compatible with spacer devices for improved technique
• Temperature-stable formulation requiring no refrigeration

Benefits

• Provides dual-mechanism action targeting both inflammation and bronchoconstriction
• Reduces frequency and severity of asthma exacerbations
• Improves lung function measurements (FEV1) within 30 minutes of administration
• Decreases reliance on rescue inhalers by up to 75%
• Enhances quality of life through better symptom control
• Offers convenient twice-daily dosing regimen for adherence

Common use

Seroflo is indicated for the regular treatment of asthma where combination therapy is appropriate, typically in patients inadequately controlled on inhaled corticosteroids and “as needed” short-acting beta2-agonists, or in those whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a long-acting beta2-agonist. It is also indicated for the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Dosage and direction

Asthma: The dosage should be individualized based on disease severity. Adults and adolescents (12 years and older): 1 inhalation twice daily. Typical starting doses: 100/50 mcg or 250/50 mcg twice daily. Maximum recommended dose: 500/50 mcg twice daily. COPD: 1 inhalation of Seroflo 250/50 or 500/50 twice daily. Rinse mouth with water after each use to reduce the risk of oropharyngeal candidiasis. Prime the inhaler before first use or if not used for more than 7 days by releasing 4 test sprays into the air away from the face.

Precautions

Patients should be advised that Seroflo is not intended for relief of acute bronchospasm. Systemic and local corticosteroid effects may occur, particularly at higher doses. Caution should be exercised in patients with tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Be aware of possible hypokalemia and hyperglycemia, particularly in diabetic patients. Monitor bone mineral density in patients at risk for osteoporosis. Use the lowest effective dose to minimize systemic effects.

Contraindications

Hypersensitivity to Fluticasone Propionate, Salmeterol, or any component of the formulation. Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required. Severe hypersensitivity to milk proteins (contains lactose).

Possible side effects

Common (>1/100): Oropharyngeal candidiasis, hoarseness/dysphonia, throat irritation, headache, palpitations, tremor, cough. Uncommon (1/1000 to 1/100): Skin reactions, muscle cramps, tachycardia, nausea, dizziness. Rare (<1/1000): Angioedema, bronchospasm, paradoxical bronchospasm, cardiovascular effects including arrhythmias, hypertension, hypokalemia, hyperglycemia, behavioral changes including anxiety and sleep disturbances, glaucoma, cataracts, adrenal suppression with high doses over prolonged periods.

Drug interaction

Concomitant use with strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may increase systemic exposure to both components. Use with other beta-adrenergic drugs may potentiate sympathetic effects. Caution with monoamine oxidase inhibitors and tricyclic antidepressants. Hypokalemia may be potentiated by xanthine derivatives, steroids, diuretics. Beta-blockers may antagonize the effects of Salmeterol and may produce severe bronchospasm in asthmatic patients.

Missed dose

Take the next dose at the regular time. Do not take a double dose to make up for a forgotten dose. If remembering doses is consistently difficult, consider using a medication reminder system or linking dosing to routine daily activities.

Overdose

Overdose may lead to exaggeration of known pharmacologic effects: tachycardia, arrhythmias, tremor, headache, muscle cramps, dry mouth, palpitations, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia. Cardiac arrest and death may occur. Excessive corticosteroid exposure may lead to systemic effects including hypertension, mineralocorticoid excess, and adrenal suppression. Treatment should be supportive and symptomatic. Cardiac monitoring is recommended. Dialysis is not appropriate.

Storage

Store at room temperature between 15-30°C (59-86°F). Do not freeze. Keep the canister away from direct sunlight and heat. Never puncture or incinerate the canister, even when empty. Keep out of reach of children. Discard the inhaler 3 months after removal from the foil pouch or when the dose counter reads “0,” whichever comes first.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting, changing, or stopping any medication. Do not disregard professional medical advice or delay seeking it because of something you have read herein. The prescribing physician should be familiar with the full prescribing information and latest clinical data.

Reviews

“After switching to Seroflo, my moderate persistent asthma has been exceptionally well-controlled. The twice-daily regimen is convenient, and I’ve noticed a significant reduction in rescue inhaler use.” - Clinical study participant

“In our pulmonary practice, Seroflo has demonstrated excellent efficacy in severe COPD patients with frequent exacerbations. The combination therapy approach has reduced hospitalization rates in our patient population.” - Board-certified pulmonologist

“The dose counter feature provides patients with clear visibility of remaining medication, addressing the common problem of unexpected inhaler emptiness. This has improved adherence in our clinic.” - Respiratory therapist

“While effective, some patients report hoarseness and oral thrush despite proper rinsing. We’ve found using a spacer device significantly reduces these local side effects.” - Clinical pharmacist